Rifampicin is one of 290 small molecule programs targeting Rhinoscleroma. It is currently in Phase 3.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
1774 competitors in Lymphoma
Rifampicin
Velban
Zofran
Norvir
Wellcovorin
Tafasitamab
Nuvigil
PEG-Intron
VP-16
R-CHOP
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details